Table 1.
I-Optimal mixture design used to optimize DCN-ODTs.
Table 2.
Experimental runs, formulation variables and measured responses of the I-Optimal mixture experimental designa,b.
Fig 1.
In-vitro mean dissolution profiles of DCN from optimized DCN-ODT (equivalent to 50 mg) compared to plain DCN and Diacerein® capsules in phosphate buffer (pH 6.8).
Fig 2.
Contour plots of the effect of formulation variables on DE (10 min) % (Y1) (a), DE (30 min) % (Y2) (b) and MDT (Y3) (c) on DCN-ODTs.
Table 3.
Statistical parameters for the measured responses.
Fig 3.
Contour plots of the effect of formulation variables on DT (Y4) (a) and WT (Y5) (b) on DCN-ODTs.
Fig 4.
Overlay plot for the effect of formulation variables on the measured responses.
Table 4.
Predicted and observed responses for the optimized DCN-ODT.
Fig 5.
Anti-inflammatory activity of optimized DCN-ODT compared to Diacerein® capsules using the rat paw edema model.
Fig 6.
Images of right hind paw of rats showing edema before (a) and 0.5 hr after administration of optimized DCN-ODT (b).